Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Krazati
Biotech
Kura posts data on drug designed to unleash KRAS inhibitors
Kura linked its drug candidate to response rates of up to 69% when given with Bristol Myers Squibb’s Krazati.
Nick Paul Taylor
May 26, 2026 10:09am
Researchers find 'highly synergistic' pancreatic cancer combo
Jun 30, 2023 12:57pm
Mirati's wait for next lung cancer med ends in phase 3 failure
May 24, 2023 4:00pm
Mirati eyes 'highest opportunity for capital' in pipeline build
Jan 9, 2023 1:37pm
Mirati pressures Amgen with Keytruda combo show in lung cancer
Dec 6, 2022 9:15am
Mirati KRAS data are 'identical' to Amgen's, researcher, CEO say
Jun 6, 2022 10:00am
